Recent Updates
Recently added Catalysts

Lorazepam

Phase 1

Healthy | Small molecule | Other |Viatris Inc.|Last Updated: Apr 24, 2024

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLEDBiomarker
Total Trials1
Total Enrollment28

FDA Designations

No designations recorded

Clinical trial landscape

Lorazepam · 1 trial · 1 indication

Phase 1 1
NCT00649818Fasting Study of Lorazepam Tablets 2 mg and Ativan Tablets 2 mgHealthy
COMPLETED28 Analytics
PHASE1COMPLETED
Fasting Study of Lorazepam Tablets 2 mg and Ativan Tablets 2 mg
HealthyUnlock trial analytics

Study Endpoints

Primary Endpoints

Bioequivalence
within 30 days
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeOTHER

Treatment Arms

ArmTypeDescription
1EXPERIMENTALLorazepam Tablets 2 mg
2ACTIVE_COMPARATORAtivan Tablets 2 mg

Interventions

NameTypeDescription
Lorazepam Tablets 2 mgDRUG2mg, single dose fasting
Ativan Tablets 2 mgDRUG2mg, single dose fasting
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and non-pregnant, non-lactating female 1. Women of childbearing potential must have negative serum (Beta HCG) pregnancy tests performed within 14 days prior to the start of the study and on the evening prior to each dose administratio...

Countries:United States
Unlock Eligibility Criteria